AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug
Seeking Alpha News (Thu, 18-Apr 7:00 AM ET)
TipRanks (Thu, 18-Apr 6:10 AM ET)
As more rare disease therapies launch, their prices are rising
Seeking Alpha News (Tue, 16-Apr 12:22 PM ET)
PRNewswire (Fri, 12-Apr 2:45 PM ET)
Business Wire (Mon, 8-Apr 11:30 AM ET)
Business Wire (Sat, 6-Apr 1:15 PM ET)
Business Wire (Sat, 6-Apr 1:15 PM ET)
Business Wire (Fri, 5-Apr 9:05 AM ET)
Business Wire (Tue, 2-Apr 8:08 PM ET)
Business Wire (Tue, 2-Apr 6:59 AM ET)
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.
As of April 18, 2024, BMY stock price climbed to $48.14 with 6,269,174 million shares trading.
BMY has a beta of 0.43, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.06 to the broad based SPY ETF.
BMY has a market cap of $97.35 billion. This is considered a Large Cap stock.
Last quarter Bristol-Myers Squibb Company reported $11 billion in Revenue and $1.70 earnings per share. This beat revenue expectation by $285 million and exceeded earnings estimates by $.17.
In the last 3 years, BMY stock traded as high as $81.44 and as low as $47.58.
The top ETF exchange traded funds that BMY belongs to (by Net Assets): VTI, VOO, SCHD, SPY, IVV.
BMY has underperformed the market in the last year with a price return of -28.5% while the SPY ETF gained +22.5%. BMY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.5% and -5.5%, respectively, while the SPY returned +6.3% and -3.7%, respectively.
BMY support price is $47.22 and resistance is $48.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY stock will trade within this expected range on the day.